TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PPV of a decrease in CoOxHb > 1 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PPV of CoOxHb < 10 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total nicotine withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall abstinence rates during treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intact parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive range of motion (dorsiflexion of the ankle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores after vaccination (pediatrician VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores after vaccination (parent VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Behavioral Pain Scale scores after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Living with Heart Failure Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Palpitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise intolerance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iron deficiency percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iron deficiency anemia percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accurate pathologic specimen acquisition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First bowel movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: degree of relapse following fixed appliance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced CU activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased use of antihistamines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of rebleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Time needed for clot absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K-10 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful NGT insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of heavy drinking days (HDDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erectile dysfunction and lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drinking to less than binge levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of responders on the HDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute liver dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Aggression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net energy balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chinese medicine syndrome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of end-point events
Endpoint domain: Mortality/survival
Primary endpoint: Pca metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Pca-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: DeltaFMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FMD%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite event rate at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in brachial artery flow‐mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psoriasis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative change in mean vessel area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in mean lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete hemidiaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Any (complete or partial) paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean time to resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mediterranean Diet Score (MDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprocedural TIMI 3 flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprocedural MBG 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery Time (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time until maximum pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: administration of ketobemidone at 24 h post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective cure rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in signs and symptoms of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in plasma NT-proBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of endometrial hyperplasia or malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of breast cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of ACR-20 responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in tender/painful joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physicians' global assessments of disease activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and interrater reliability in identifying gross hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum concentration of digoxin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum drug concentration‐time curve from time zero to 120 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEO-PI-R agreeableness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NEO-PI-R conscientiousness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean serum phosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SBP improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total work performed during the 30‐second test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urinary excretion of serotonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-h urinary excretion of noradrenaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-h urinary excretion of 5-HIAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Discordance between outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal CGA-domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGA-based interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simplified Menopausal Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Rating Depression Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: level of daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduction of low-density lipoprotein cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of vessel wall area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shoulder pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (SF-36 total score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in fast-food restaurant purchases
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in purchases at food stores for breakfast
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HEI-2010 dairy component scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: cycle ergometer workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of individual behavioural goals
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvements in treatment effects for patients with mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Basal forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: S100β protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative Ht levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S100 area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain intensity at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal sucrose urinary excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lactulose/mannitol urinary excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alteration of gastric permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to treatment failure (TTF)
Endpoint domain: Mortality/survival
Primary endpoint: mean dose of bolus epidural ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median pain score at postoperative 6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of large LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: decrease in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pulse changes from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment-emergent cardiovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in total Clinical Global Impressions‐Severity of Illness scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study subjects responding (40% or greater BPRS total score improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated hemoglobin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-CVD mortality
Endpoint domain: Mortality/survival
Primary endpoint: stone clearance after the first session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PC20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fear of the future
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical limitations and pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Elimination half-life of etizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of stroke or TIA
Endpoint domain: Mortality/survival
Primary endpoint: Rate of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: LDL cholesterol level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of anaemia recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: third-trimester maternal anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum troponin T concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breast relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postoperative procalcitonin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: frequency of postoperative fever
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical attachment level (CAL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude lifetime prevalence rate of epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: radiographic progression or death
Endpoint domain: Mortality/survival
Primary endpoint: onset rate of severe psychiatric manifestations
Endpoint domain: Adverse events/effects
Primary endpoint: requirement for antidepressants and benzodiazepines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of patients with fair or poor recoveries
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total FaCE score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: lacrimal control scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical effectiveness of technician-assisted iCBT programs for GAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: onset time of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in hsTnT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: induction-abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamol to phenacetin AUC ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20, ACR50, and ACR70 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission or low disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from persistent or worsening symptoms of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean VAS for pain from hour 6 to day 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of intracerebral hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Risk of subarachnoid hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Risk of cerebral infarction
Endpoint domain: Mortality/survival
Primary endpoint: Mean FBG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-hour freedom from the MBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute dermal toxicity of grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of inactivated vaccine for virus isolation or increase in serum antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of fever with neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Median duration of grade IV neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of confirmed infections
Endpoint domain: Adverse events/effects
Primary endpoint: Interrater agreement for overall grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater agreement for defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opioid use disorder criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presentation visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infiltrate or scar size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) of lamivudine and abacavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of once-daily dosing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for once-daily dosing over twice-daily
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Supplementary analgesia required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of confident diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with physician explanations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient confidence in the physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BRT (Blink Reflex Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: No tender, swollen joints (NTSJ) at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfaction tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: working memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Amenorrhea occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: risk of septic complications
Endpoint domain: Adverse events/effects
Primary endpoint: gastric pH alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Side effects of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Virologic suppression at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extraversion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Openness to Experience scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total ischemic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes